89793-09-9

Basic information

• Product Name: 2-Chloro-4,6-diMethyl-3-nitropyridine
• Synonyms: 2-Chloro-4,6-diMethyl-3-nitropyridine
• CAS NO: 89793-09-9
• Molecular Formula: C₇H₇ClN₂O₂
• Molecular Weight: 186.59568
• Mol File: 89793-09-9.mol
• Article Data: 8

Chemical Properties

• Melting Point: 45 °C
• Boiling Point: 137 °C(Press: 1 Torr)
• Appearance: /
• Density: 1.342±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -0.83±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-4,6-diMethyl-3-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4,6-diMethyl-3-nitropyridine(89793-09-9)
• EPA Substance Registry System: 2-Chloro-4,6-diMethyl-3-nitropyridine(89793-09-9)

Safety Data

• Hazardous Substances Data: 89793-09-9(Hazardous Substances Data)

Usage

General Description

2-Chloro-4,6-dimethyl-3-nitropyridine is a chemical compound with the molecular formula C7H7ClN2O2. It is a nitro pyridine derivative with a chlorine atom and two methyl groups attached to the pyridine ring. 2-Chloro-4,6-diMethyl-3-nitropyridine is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is known for its versatile reactivity and is often employed in various organic reactions including nucleophilic substitution, cross-coupling reactions, and heterocyclic syntheses. Additionally, its nitro group provides the potential for reduction to form amines, making it a valuable intermediate in organic synthesis. Due to its important role in the production of various chemicals, 2-Chloro-4,6-dimethyl-3-nitropyridine is a valuable compound in the field of organic chemistry.

Upstream product

• 626-35-7 nitroacetic acid ethyl ester 
• 123-54-6 acetylacetone 
• 22934-13-0 4,6-dimethyl-3-nitro-2(1H)-pyridinone 
• 22934-13-0 5-nitro-6-hydroxy-2,4-dimethylpyridine 

Downstream Products

• 415911-39-6 3-{4-[(4,6-Dimethyl-3-nitro-2-pyridinyl)amino]phenyl}propanoic Acid 
• 415907-57-2 2-{4-[(4,6-dimethyl-3-nitro-2-pyridinyl)amino]phenyl}ethanol 
• 415907-63-0 2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)phenyl]ethylamine 
• 415907-59-4 2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)phenyl]ethyl propionate 
• 415907-60-7 2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)phenyl]ethanol 
• 415907-61-8 3-[4-(2-chloroethyl)phenyl]-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine 
• 415907-58-3 2-{4-[(3-amino-4,6-dimethyl-2-pyridinyl)amino]phenyl}ethanol 
• 415902-95-3 2-ethyl-5,7-dimethyl-3-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-3H-imidazo[4,5-b]pyridine 
• 415912-16-2 (2S)-1-{4-[(4,6-dimethyl-3-nitro-2-pyridinyl)amino]phenyl}-2-propanol 
• 415907-65-2 1-{4-[(4,6-dimethyl-3-nitro-2-pyridinyl)amino]phenyl}-2-propanol 

Relevant articles and documents

2-Sulfonylpyridines as Tunable, Cysteine-Reactive Electrophiles

The emerging use of covalent ligands as chemical probes and drugs would benefit from an expanded repertoire of cysteine-reactive electrophiles for efficient and diverse targeting of the proteome. Here we use the endogenous electrophile sensor of mammalian cells, the KEAP1-NRF2 pathway, to discover cysteine-reactive electrophilic fragments from a reporter-based screen for NRF2 activation. This strategy identified a series of 2-sulfonylpyridines that selectively react with biological thiols via nucleophilic aromatic substitution (SNAr). By tuning the electrophilicity and appended recognition elements, we demonstrate the potential of the 2-sulfonylpyridine reactive group with the discovery of a selective covalent modifier of adenosine deaminase (ADA). Targeting a cysteine distal to the active site, this molecule attenuates the enzymatic activity of ADA and inhibits proliferation of lymphocytic cells. This study introduces a modular and tunable SNAr-based reactive group for targeting reactive cysteines in the human proteome and illustrates the pharmacological utility of this electrophilic series.

SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof.

COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS

The instant invention relates to a combination of an EP4-receptor antagonist and an alpha-2-delta ligand, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly inflammatory,